Trials / Completed
CompletedNCT05117554
Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
A First-in-human, Participant and Investigator-blinded, Randomized, Placebo-controlled, Single-and Multiple-Ascending Dose Study With Drug-Drug Interaction, to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of AB521, in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and tolerability, pharmacokinetic, and pharmacodynamic profile, and drug-drug interaction (DDI) of casdatifan in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | casdatifan | Capsule |
| DRUG | Placebo | Capsule |
| DRUG | Midazolam | Syrup solution |
Timeline
- Start date
- 2021-11-09
- Primary completion
- 2023-02-17
- Completion
- 2023-02-17
- First posted
- 2021-11-11
- Last updated
- 2024-10-17
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT05117554. Inclusion in this directory is not an endorsement.